180 related articles for article (PubMed ID: 8900364)
1. Alendronate: a bisphosphonate for treatment of osteoporosis.
Kirk JK; Spangler JG
Am Fam Physician; 1996 Nov; 54(6):2053-60. PubMed ID: 8900364
[TBL] [Abstract][Full Text] [Related]
2. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis.
Chailurkit LO; Jongjaroenprasert W; Rungbunnapun S; Ongphiphadhanakul B; Sae-tung S; Rajatanavin R
J Bone Miner Metab; 2003; 21(6):421-7. PubMed ID: 14586800
[TBL] [Abstract][Full Text] [Related]
3. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
4. Postmenopausal osteoporosis and alendronate.
Pérez-López FR
Maturitas; 2004 Jul; 48(3):179-92. PubMed ID: 15207883
[TBL] [Abstract][Full Text] [Related]
5. [Effect of alendronate therapy on bone turnover--results of a multicenter study].
Payer J; Killinger Z; Masaryk P; Tomková S; Kmecová Z; Ondrejková J; Necas L; Smoterová J; Ondrejka P; Kratochvilová H
Vnitr Lek; 2000 Oct; 46(10):689-92. PubMed ID: 11344627
[TBL] [Abstract][Full Text] [Related]
6. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
Adachi JD
Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
[TBL] [Abstract][Full Text] [Related]
8. Osteoporosis. Efficacy and safety of a bisphosphonate dosed once weekly.
Baran D
Geriatrics; 2001 Mar; 56(3):28-32. PubMed ID: 11252758
[TBL] [Abstract][Full Text] [Related]
9. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials with bisphosphonates.
Lombardi A; Santora AC
Ann Ital Med Int; 1992; 7(3 Suppl):158S-165S. PubMed ID: 1297394
[TBL] [Abstract][Full Text] [Related]
11. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
12. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.
Guañabens N; Parés A; Ros I; Alvarez L; Pons F; Caballería L; Monegal A; Martínez de Osaba MJ; Roca M; Peris P; Rodés J
Am J Gastroenterol; 2003 Oct; 98(10):2268-74. PubMed ID: 14572578
[TBL] [Abstract][Full Text] [Related]
13. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
14. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis.
Sugiyama T; Tanaka H; Kawai S
N Engl J Med; 2004 Jan; 350(2):189-92; author reply 189-92. PubMed ID: 14714280
[No Abstract] [Full Text] [Related]
15. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
16. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P
Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis.
Greenspan SL; Harris ST; Bone H; Miller PD; Orwoll ES; Watts NB; Rosen CJ
Am Fam Physician; 2000 May; 61(9):2731-6. PubMed ID: 10821153
[TBL] [Abstract][Full Text] [Related]
20. The clinical tolerability profile of alendronate.
Watts N; Freedholm D; Daifotis A
Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
